Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies

Anticancer Research

Volumn 34, Issue 6, 2014, Pages 3189-3196

  Kim, Hyun Jung ^a   Choi, Eun Young ^a   Jin, Hyun Jung ^a   Shin, Kyeong Cheol ^a  

^a Yeungnam University College of Medicine   (South Korea)

Author keywords

EGFR; Epidermal growth factor receptor mutation; Lung adenocarcinoma; Small biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER STAGING; CLINICAL FEATURE; DNA SEQUENCE; EXON; FEMALE; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; ACINAR CELL CARCINOMA; ADENOCARCINOMA; BIOPSY; COLLOID CARCINOMA; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION; GENETICS; LUNG TUMOR; MIDDLE AGED; MUTATION; PROGNOSIS; SMALL BIOPSY; VERY ELDERLY;

EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION; LUNG ADENOCARCINOMA; SMALL BIOPSY;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, ACINAR CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84906319278     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber D: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
3. Inoue A, Kobayashi K, Usui K, Maemondo M, Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, Miyazawa H, Tanaka T, Ikebuchi K, Nukiwa T, Morita S and Hagiwara K: First-line gefitinib for patients with advanced non-smallcell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27: 1394-1400, 2009.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA and Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
6. Hsieh RK, Lim KH, Kuo HT, Tzen CY and Huang MJ: Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128: 317-321, 2005.
7. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, Tabata M, Ueoka H, Tanimoto M, Date H, Gazdar AF and Shimizu N: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
8. Edge SB, Byrd DR, Comptom CC, Fritz AG, Greene FL and Trotti A: AJCCCancer Staging Manual. 7th ed.New York, Springer, 2010.
9. Brambilla E, Travis WD, Colby T V, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. EurRespir J 18: 1059-1068, 2001.
10. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC and Gould M: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 8: 381-385, 2011.
11. Kim MJ, Shin KC and Lee KH: Intron 1 polymorphism, mutation and the protein expression of epidermal growth factor receptor in relation to the gefitinib sensitivity of Korean lung cancer patients. Korean J Pathol 43: 509-516, 2009.
12. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, Nakatomi K, Fujino S, Hayashi T, Nakamura Y, Tsukamoto K and Kohno S: Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 60: 136-140, 2008.
13. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA and Tsao MS: Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 3: 527-529, 2008.
14. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS and Chung JH: High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF1 expressions, and clinical features. J Thorac Oncol 7: 323-330, 2012.
15. Yatabe Y, Matsuo K and Mitsudomi T: Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29: 2972-2977, 2011.
16. Kim HR, Ahn JR, Lee JG, Bang DH, Ha S-J, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA, Riely GJ, Kim JH and Cho BC: The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma.Yonsei Med J 54: 865-874, 2013.
17. Choi YH, Lee JK, Kang HJ, Lee TS, Kim HR, Kim CH, Koh JS, Baek HJ, Lee JC and Na II: Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer. J ThoracOncol 5: 1949-1952, 2010.
18. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ and Taron M: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967, 2009.
19. Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S and Jambhekar N: Frequency of EGFRmutations in 907 lung adenocarcioma patients of Indian ethnicity. PloS one 8: e76164, 2013.
20. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: Aprospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9: 154-162, 2014.
21. Ueno T, Toyooka S, Suda K, Soh J, Yatabe Y, Miyoshi S, Matsuo K and Mitsudomi T: Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer 78: 207-211, 2012.
22. Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W and Chen H: Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res 18: 1947-1953, 2012.
23. Wu SG, Hu FC, Chang YL, Lee YC, Yu CJ, Chang YC, Wu JY, Shih JY and Yang PC: Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. EurRespir J 41: 417-424, 2013.
24. Shim HS, Lee da H, Park EJ and Kim SH: Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med 135: 1329-1334, 2011.
25. Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D and John T: Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol 8: 461-468, 2013.
26. Ye X, Zhu ZZ, Zhong L, Lu Y, Sun Y, Yin X, Yang Z, Zhu G and Ji Q: High T790M detection rate in TKI-naive NSCLC with EGFR-sensitive mutation: truth or artifact? J Thorac Oncol 8: 1118-1120, 2013.
27. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih J Y, Yu SL and Yang PC: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-smallcell lung cancer. J Clin Oncol 30: 433-440, 2012.
28. Han SW, Kim TY, Lee KH, Hwang PG, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS and Bang YJ: Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-smallcell lung cancer patients. Lung Cancer 54: 201-207, 2006.
29. Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, Matsumoto S, Ohmatsu H, Nagai K, Ohe Y and Ochiai A: Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol 139: 1691-1700, 2013.